E-mail

E-mail a Wiley Online Library Link

Jennifer A. Crozier, Alvaro Moreno-Aspitia, Karla V. Ballman, Amylou C. Dueck, Barbara A. Pockaj and Edith A. Perez Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831 Cancer 119

Article first published online: 12 APR 2013 | DOI: 10.1002/cncr.28051

In patients with resected, HER2-positive, early stage breast cancer, a baseline body mass index of ≥25 kg/m2 is associated with a lower 5-year disease-free survival. Adjuvant trastuzumab leads to an improvement in disease-free survival for all patients, regardless of their body mass index.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH